Which MPs and peers raise respiratory (asthma/copd) most in Parliament?

Jim Shannon, Dr Caroline Johnson, Ashley Dalton lead the ranking of MPs and peers on respiratory (asthma/copd), based on every Hansard contribution since 9 July 2024.

How is the respiratory (asthma/copd) ranking calculated?

Vital Signs ranks MPs and members of the House of Lords by a weighted score of their Hansard contributions on Respiratory (asthma/COPD) — speeches, written questions and committee work — over the course of this Parliament (since 9 July 2024). Ministerial statements and debate speeches carry more weight than written answers; every contribution counts at full weight however early in the Parliament it was made. Contributions are matched to this topic on whole-word keyword matching, so "send" is never mistaken for SEND and "career" is never mistaken for care. Ministers and shadow ministers are labelled, because answering on a brief is their job rather than a choice to raise it; their scores are shown as-is, not adjusted.

Respiratory (asthma/COPD): which MPs and peers raise it most

Since the start of this Parliament, 138 MPs and peers have raised Respiratory (asthma/COPD) in Hansard debates, written questions and committee work. Debate has intensified recently: the last two months produced 340% more mentions than the two months before that.

The debate has been led most vocally by Jim Shannon (Democratic Unionist Party, Strangford), whose score of 45.0 is 1.3× that of the next most active contributor, Dr Caroline Johnson.

By party, Labour leads with 55% of weighted activity, followed by Conservative (15%) and Liberal Democrat (14%). The House of Commons accounts for 87% of all weighted activity on Respiratory (asthma/COPD).

Most cited doctors & academics

UK clinicians and academics most frequently quoted as expert sources in press coverage of respiratory (asthma/copd).

Professor Ramesh Kurukulaaratchy
1 citation
Professor of respiratory medicine and allergy at the University of Southampton
“explains how his team's recent work recognising distinct patterns of multimorbidity in severe asthma may help clinicians move beyond an airway-centred approach towards more holistic, multidisciplinary care”
Why multimorbidity matters in severe asthma: looking beyond the airways
Markus Ege
1 citation
epidemiologist, LMU University Hospital and the Institute of Asthma and Allergy Prevention at Helmholtz Munich in Germany
“Girls and boys who grow up on farms and are exposed to a wider variety of microbes have the problem far less often”
'Natural Protection From Asthma And Allergies': Scientists Isolate Bacteria Behind The Immune System Farm Effect
Giulia Pagani
1 citation
bioinformatician, Helmholtz Munich
“We identified a small number of bacteria, which we can now pinpoint down to the species level, such as Romboutsia timonensis and Glutamicibacter arilaitensis”
'Natural Protection From Asthma And Allergies': Scientists Isolate Bacteria Behind The Immune System Farm Effect
Dr. Rebecca Mura
1 citation
Department of Biomedical Imaging and Image-guided Therapy at the Medical University of Vienna in Vienna, Austria
“First author of the SOLACE study published on 29 July in Insights into Imaging”
Europe’s lung screening training gaps sharpen focus on implementation
Dr. Christian Bijan Fink
1 citation
University Hospital Düsseldorf in Düsseldorf, Germany
“lung cancer screening as "more than a CT"”
Europe’s lung screening training gaps sharpen focus on implementation
Yi Larson
1 citation
CEO of Expedition Therapeutics
“You take this pill once a day, and it can target that underlying inflammation that all the COPD patients have. This felt like it could become a backbone of care for patients.”
A COPD drug from China draws $115M in venture funding
Brett Zbar
1 citation
Managing Director at General Atlantic
“General Atlantic has benefited from the good fortune of having a team and a real presence in China, where the investment firm has found first or best-in-class assets.”
A COPD drug from China draws $115M in venture funding
Ameera Patel
1 citation
Chief Executive of TidalSense
“Our ambition is really bold and broad, and it is to have a really significant impact at a population level on chronic respiratory diseases like COPD and asthma. We want the test to be available to anyone the first time they present with symptoms, so there's no bias in accessibility based on where you live, your socio-economic status or your ethnicity.”
TidalSense raises £14m to expand five-minute COPD test across NHS

Vital Signs — Respiratory (asthma/COPD)

Vital Signs — Respiratory (asthma/COPD)

Mentions since the start of this Parliament

How the ranking works

Debate analysis

Media coverage

Most cited doctors & academics